PT Kedoya Adyaraya Tbk

PT Kedoya Adyaraya Tbk

IIDX:RSGK
1,100.00
IDR
0.00
(0.00%)
36.75EPS
27.34P/E
934.32BMarket Cap
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
261.37
306.24
317.23
877.61
386.32
401.65
474.44
505.11
550.32
Basic EPS, GAAP
13.69
24.4
21.5
106.69
28.16
27.09
42.69
37.12
36.76
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
5.38
- -
- -
- -
86
96
11
- -
- -
Book Value per Share
300.59
520.5
522.58
907.73
876.22
807.08
858.01
891.49
911.91
Tangible Book Value per Share
300.59
520.5
522.58
907.73
876
794.47
844.92
879.72
900.76
Basic Weighted Avg Shares
930
930
930
496
930
930
930
930
930
Sales/Revenue/Turnover
242,988
284,704
294,917
435,196
359,156
373,400
441,072
469,593
511,620
Operating Margin (%)
3.67
7.66
10.36
21.12
11.44
7.11
11.7
9.61
9.64
Depreciation Expense
13,670
12,770
11,110
11,591
11,563
13,198
9,974
10,982
11,681
Net Income, GAAP
12,723
22,680
19,989
52,909
26,180
25,189
39,692
34,507
34,173
Effective Tax Rate (%)
328.08
51.41
84.06
34.98
40.86
20.1
30.17
23.81
25.02
Profit Margin (%)
5.24
7.97
6.78
12.16
7.29
6.75
9
7.35
6.68
Working Capital
-182,475
-160,904
-3,294
217,210
160,632
81,476
57,582
233
26,606
LT Debt
117,790
3,072
133,265
12,539
- -
- -
- -
- -
- -
Total Equity
283,891
475,336
490,790
844,219
815,534
751,162
798,461
829,769
848,759
Return on Invested Capital (%)
- -
2.29
0.84
7.93
3.02
2.97
4.92
4.36
4.51
Return on Capital (%)
- -
9.39
6.25
8.12
3.27
3.23
5.14
4.63
4.77
Return on Common Equity (%)
- -
5.94
4.12
7.96
3.16
3.22
5.13
4.24
4.11

Capital Structure

IDR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
21,000
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
930
930
930
Market Capitalization
- -
1,450,293
934,323

Working Capital

IDR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
127,218
126,560
122,820
Cash, Cash Equivalents & STI
61,360
50,447
41,964
Accounts Receivable, Net
42,205
45,205
51,550
Inventories
14,731
15,312
14,386
Total Current Liabilities
126,984
103,443
96,215
Payables & Accruals
- -
- -
- -
ST Debt
21,000
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

IDR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
14.19%
3.92%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
30.98%
-13.06%
Sales/Revenue/Turnover
- -
11.73%
6.47%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

IDR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
116,986
107,317
109,654
106,587
441,072
2025
106,954
112,402
122,706
127,531
469,593
2026
127,712
133,671
- -
- -
- -

Quarterly Earnings Per Share

IDR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
16.59
10.65
8.87
6.59
42.69
2025
8.88
11.82
9.1
7.31
37.12
2026
10.08
10.27
- -
- -
- -

Quarterly Dividends Per Share

IDR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
11
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Juniwati Gunawan
Full Time Employees
766
Sector
Health services
Industry
Hospital/Nursing management
Address
Jalan Panjang Arteri No.26 Jakarta JK Indonesia 11520
IPO Date
Sep 8, 2021
Business
PT Kedoya Adyaraya Tbk owns and operates private hospitals in Indonesia, providing comprehensive healthcare services through its facilities including EMC Grha Kedoya Hospital in West Jakarta and EMC Cibitung Hospital (formerly Grha MM2100 Hospital) in Bekasi, West Java; core offerings encompass inpatient and outpatient rooms, operating rooms, delivery rooms, HCU, ICU, ICCU, PICU, NICU, emergency rooms, endoscopy, CT-scan, mammography, mobile X-ray, general X-ray, 4D ultrasound, fluoroscopy, catheterization laboratory, spirometry, hemodialysis, laser treatments, medical rehabilitation, pharmacy, radiology, laboratories for chemistry, hematology, microbiology, and immunology, as well as specialized centers for trauma, stroke care, cardiology, bariatric surgery, oncology, hyperbaric oxygen therapy, and robotic-assisted rehabilitation using tools such as LEXO and DIEGO; additional specialties include general surgery, orthopedics, urology, cardiothoracic surgery, neurosurgery, internal medicine, nephrology, obstetrics, gynecology, neurology, pulmonology, pediatrics, acupuncture, and occupational medicine. The company, founded in 1990 and headquartered at Jl. Panjang Arteri No. 26, Kedoya Utara, Kebon Jeruk, West Jakarta, serves patients across Indonesia with a focus on modern private hospitals featuring international-standard accreditations such as Joint Commission International (JCI) Gold Seal for EMC Grha Kedoya and Paripurna level national accreditation for both facilities; EMC Cibitung Hospital operates via subsidiary PT Sinar Medika Sejahtera. PT Kedoya Adyaraya Tbk, a subsidiary of PT Sarana Meditama Metropolitan Tbk, underwent significant ownership changes including PT Sarana Meditama Metropolitan Tbk's acquisition of a controlling 66% stake in November 2021 and an additional 13.84% stake in January 2022; it listed on the Indonesia Stock Exchange in September 2021 with 185,940,000 shares offered at IDR 200 each following OJK approval in August 2021 and executed a capital increase via public offering; recent operational investments include substantial fixed asset acquisitions and advances exceeding IDR 6 billion in the first quarter of 2025 alongside a revolving loan facility with PT Bank CIMB Niaga Tbk involving related parties PT Pratama Medika and PT Sinar Medika Sejahtera, supporting revenue growth to IDR 441.07 billion in 2024, up 18.12% from the prior year.